Investor Overview

Webcast ImageWebcast
AtriCure, Inc. Earnings Conference Call (Live)
11/01/18 at 4:30 p.m. ET
Webcast ImageWebcast
AtriCure, Inc. at Morgan Stanley Global Healthcare Conference (Replay)
09/14/18 at 1:00 p.m. ET
Webcast ImageWebcast
AtriCure, Inc. at Canaccord Genuity 38th Annual Growth Conference  (Replay)
08/09/18 at 12:00 p.m. ET
Webcast ImageWebcast
Q2 2018 AtriCure, Inc. Earnings Conference Call (Replay)
08/01/18 at 4:30 p.m. ET

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$30.18 + 0.230.77%102,534
Previous CloseToday's OpenIntraday HighIntraday Low
$29.95$29.44$30.18$28.82
Exchange: NASDAQ (US Dollar)
10/23/18 1:25 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
10/18/18
Download Documentation Investor Presentation
08/01/18
Download Documentation Q2 2018 Earnings Call Transcript
06/26/18
Download Documentation Analyst Meeting Transcript

All Recent News

DateTitle 
10/22/18AtriCure to Participate in Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--Oct. 22, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2018 Healthcare Conference in New York City on Wednesday, November 14, 2018. Management is scheduled to present at... 
Printer Friendly Version
10/11/18AtriCure to Announce Third Quarter 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Oct. 11, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 1, 2018 to discuss its third quarter 2018 financial ... 
Printer Friendly Version
10/04/18AtriCure Announces Pricing of Public Offering of Common Stock
MASON, Ohio--(BUSINESS WIRE)--Oct. 4, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 2.5 million shares of its common stock at a price to the public of $30.75 per share pursuant to its existing shelf registration statement. Net proceeds to AtriCure from the offering are expected to be approximatel... 
Printer Friendly Version
10/03/18AtriCure Reports Preliminary Financial Results for Third Quarter 2018
MASON, Ohio--(BUSINESS WIRE)--Oct. 3, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the third quarter of 2018. Preliminary and unaudited revenue for the third quarter of 2018 is expected to be approximately $49.9 million, reflecting growth of approximately 18.5% over the third quarter... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
10/22/18AtriCure to Participate in Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--Oct. 22, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2018 Healthcare Conference in New York City on Wednesday, November 14, 2018. Management is scheduled to present at... 
Printer Friendly Version
10/11/18AtriCure to Announce Third Quarter 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Oct. 11, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 1, 2018 to discuss its third quarter 2018 financial ... 
Printer Friendly Version
10/04/18AtriCure Announces Pricing of Public Offering of Common Stock
MASON, Ohio--(BUSINESS WIRE)--Oct. 4, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 2.5 million shares of its common stock at a price to the public of $30.75 per share pursuant to its existing shelf registration statement. Net proceeds to AtriCure from the offering are expected to be approximatel... 
Printer Friendly Version
10/03/18AtriCure Reports Preliminary Financial Results for Third Quarter 2018
MASON, Ohio--(BUSINESS WIRE)--Oct. 3, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the third quarter of 2018. Preliminary and unaudited revenue for the third quarter of 2018 is expected to be approximately $49.9 million, reflecting growth of approximately 18.5% over the third quarter... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
08/28/18AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio--(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohor... 
Printer Friendly Version
06/05/18AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes... 
Printer Friendly Version
04/25/17AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, which makes it the most widely used of all d... 
Printer Friendly Version
03/14/17AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
11/01/18 
4:30 p.m. ET
AtriCure, Inc. Earnings Conference Call
11/14/18 
1:15 p.m. ET
AtriCure, Inc. at Stifel 2018 Healthcare Conference
11/15/18
AtriCure, Inc. at Canaccord Genuity 12th Annual Medical Technologies and Diagnostics Forum
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.